The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
Open accessAbstract
Purpose: Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored. Patients and Methods: One hundred sixty-nine children diagnosed with stage 4 NB (1988 to 2008) were enrolled onto consecutive anti-GD2 murine MoAb 3F8 ± GM-CSF ± 13-cis-retinoic acid (CRA) protocols after achieving first remission (complete remission/very good partial remission). Patients enrolled in regimen A (n = 43 high-risk [HR] patients) received 3F8 alone; regimen B (n = 41 HR patients), 3F8 + intravenous GM-CSF + CRA, after stem-cell transplantation (SCT); and regimen C (n = 85), 3F8 + subcutaneous GM-CSF + CRA, 46 of 85 after SCT, whereas 28 of 85 required additional induction therapy and were deemed ultra high risk (UHR). Marrow minimal residual disease (MRD) was measured by quantitative reverse transcription polymerase chain reaction. Survival probability was calculated by the Kaplan-Meier method, and prognostic variables were analyzed by multivariate Cox regression model. Results: At 5 years from the start of immunotherapy, progression-free survival (PFS) improved from 44% for HR patients receiving regimen A to 56% and 62% for those receiving regimens B and C, respectively. Overall survival (OS) was 49%, 61%, and 81%, respectively. PFS and OS of UHR patients were 36% and 75%, respectively. Relapse was mostly at isolated sites. Independent adverse prognostic factors included UHR (PFS) and post–cycle two MRD (PFS and OS), whereas the prognostic factors for improved outcome were missing killer immunoglobulin-like receptor ligand (PFS and OS), human antimouse antibody response (OS), and regimen C (OS). Conclusion: Retrospective analysis of consecutive trials from a single center demonstrated that MoAb 3F8 + GM-CSF + CRA is effective against chemotherapy-resistant marrow MRD. Its positive impact on long-term survival can only be confirmed definitively by randomized studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S., Martin, P. L., Pullen, D. J., Viswanatha, D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 842
Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., Clark, R. E., Apperley, J. F., Milojkovic, D., Bua, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6565 · Cited by 476
Cheung, N. K., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., & Berger, N. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1430 · Cited by 417
Self-citationHsu, K. C., Liu, X.-R., Selvakumar, A., Mickelson, E., O’Reilly, R. J., & Dupont, B. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5118 · Cited by 381
London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3392 · Cited by 318
Homesley, H. D., Filiaci, V., Markman, M., Bitterman, P., Eaton, L., Kilgore, L. C., Monk, B. J., & Ueland, F. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4907 · Cited by 260
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Kramer, K., Kushner, B. H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzonico, P., Humm, J. L., Xu, H., Wolden, S. L., Souweidane, M. M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0038-7 · Cited by 247
Self-citationCytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Cho, D., Shook, D. R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., & Campana, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0735 · Cited by 234
Kushner, B. H., Kramer, K., & Cheung, N.-K. V. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4189 · Cited by 208
Self-citationGeorge, R. E., Li, S., Medeiros-Nancarrow, C., Neuberg, D., Marcus, K., Shamberger, R. C., Pulsipher, M., Grupp, S. A., & Diller, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6986 · Cited by 205
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 205
Cheung, N. K., Kushner, B. H., Cheung, I. Y., Kramer, K., Canete, A., Gerald, W., Bonilla, M. A., Finn, R., Yeh, S. J., & Larson, S. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3053 · Cited by 199
Self-citationLong-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Laverdière, C., Liu, Q., Yasui, Y., Nathan, P. C., Gurney, J. G., Stovall, M., Diller, L. R., Cheung, N.-K., Wolden, S., Robison, L. L., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp230 · Cited by 189
Self-citationDelgado, D. C., Hank, J. A., Kolesar, J., Lorentzen, D., Gan, J., Seo, S., Kim, K., Shusterman, S., Gillies, S. D., Reisfeld, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2211 · Cited by 179
Barker, E., Mueller, B. M., Handgretinger, R., Herter, M., Yu, A. L.-T., & Reisfeld, R. A. (1991) · PubMed · Cited by 164
Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma
Kushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7272 · Cited by 137
Self-citationMatthay, K. K., Atkinson, J. B., Stram, D. O., Selch, M. T., Reynolds, C. P., & Seeger, R. C. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2226 · Cited by 133
Cheung, N. V., Sowers, R. S., Vickers, A. J., Cheung, I. Y., Kushner, B. H., & Gorlick, R. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6011 · Cited by 122
Self-citationDisialoganglioside Directed Immunotherapy of Neuroblastoma
Modak, S. I., & Cheung, N. V. (2007) · Cancer Investigation · doi:10.1080/07357900601130763 · Cited by 121
Self-citationSchmidt, M. C., Simon, T., Hero, B., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.013 · Cited by 95
Katzenstein, H. M., Cohn, S. L., Shore, R. M., Bardo, D. M. E., Haut, P. R., Olszewski, M., Schmoldt, J., Liu, D., RADEMAKER, A. W., & Kletzel, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.144 · Cited by 95
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
Petrella, T. M., Quirt, I. C., Verma, S., Haynes, A. E., Charette, M. L., & Bak, K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.04.003 · Cited by 87
Leung, W. H., Handgretinger, R., Iyengar, R. V., Turner, V., Holladay, M. S., & Hale, G. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603913 · Cited by 81
Cheung, N. K., Guo, H.-F., Heller, G., & Cheung, I. Y. (2000) · PubMed · Cited by 79
Self-citationCheung, I. Y., Feng, Y., Gerald, W. L., & Cheung, N. V. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0541 · Cited by 77
Self-citationCheung, I. Y., Hsu, K. C., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6236 · Cited by 72
Self-citationKushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1147-3 · Cited by 43
Self-citationKushner, B. H., Cheung, I. Y., Kramer, K., Modak, S. I., & Cheung, N. V. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20765 · Cited by 22
Self-citation91st Annual Meeting of the American Association for Cancer Research
Speirs, V., & Schmeichel, K. L. (2000) · Breast Cancer Research · doi:10.1186/bcr71 · Cited by 15
Cited by
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Self-citationRadioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Self-citationHeczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J. M., Owens, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30578-3 · Cited by 418
Metadata
- Authors
- Cheung, N.-K. V., Cheung, I. Y., Kushner, B. H., Ostrovnaya, I., Chamberlain, E., Kramer, K., & Modak, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-09-10
- Volume
- 30
- Issue
- 26
- Pages
- 3264-3270
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2151310238
- Cited by
- 263
- References
- 35
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.